NEWFlashcards for any set of questions, quick-reference tables for breast, lung and prostate, and a month of access for every colleague you refer. See what changed

Breast: Metastatic HR-positive CDK4/6

Free question published 06 November 2026

BreastMetastatic HR-positive CDK4/6

A 41-year-old premenopausal woman is diagnosed with de novo bone-only metastatic breast cancer that is ER-positive, HER2-negative. She has no visceral crisis and good performance status. The team plans first-line endocrine-based therapy with ovarian function suppression using goserelin. What should be added to endocrine therapy to maximise overall survival?

  1. ATrastuzumab
  2. BA CDK4/6 inhibitor (ribociclib)
  3. CEverolimus as first-line addition
  4. DA PARP inhibitor irrespective of BRCA status
  5. EA taxane chemotherapy backbone

Why B is correct

MONALEESA-7 evaluated pre- and perimenopausal women with HR-positive, HER2-negative advanced breast cancer receiving endocrine therapy plus goserelin, and showed that adding the CDK4/6 inhibitor ribociclib improved median overall survival (58.7 vs 48.0 months, HR 0.76). For this premenopausal woman with HR-positive HER2-negative metastatic disease, a CDK4/6 inhibitor added to endocrine therapy with ovarian suppression is the standard first-line approach.

And why the others are not

  • AIncorrect. Trastuzumab targets HER2; this disease is HER2-negative.
  • CIncorrect. Everolimus is a later-line option after progression on endocrine therapy, not a first-line addition here.
  • DIncorrect. A PARP inhibitor is indicated only with a germline BRCA mutation, not irrespective of BRCA status.
  • EIncorrect. Chemotherapy is reserved for visceral crisis or endocrine-resistant disease; this patient has indolent bone-only disease suited to endocrine-based therapy.

Source MONALEESA-7 - ribociclib in premenopausal HR-positive advanced breast cancer — Im SA, Lu YS, Bardia A, et al. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer (MONALEESA-7). N Engl J Med. 2019;381(4):307-316. Updated OS: Lu YS, et al. Clin Cancer Res. 2022;28(5):851-859.

Sitting in February? Follow the twenty-week plan.

2,500+ cited questions like this one are waiting in the vault.

See plans and pricing